Arcutis Biotherapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing dermatology therapies, including ARQ-151, ARQ-154, ARQ-252 and ARQ-255. The report was filed February 5, 2021, with an earliest reported event date of February 1, 2021. It disclosed preliminary year-end 2020 liquidity information and a subsequent underwritten public offering of common stock.
Financial condition and key metrics
- Preliminary cash, cash equivalents, restricted cash and marketable securities were approximately $286.0 million as of December 31, 2020.
- The preliminary liquidity figure was unaudited, subject to change, and provided without assurance from Ernst & Young LLP.
- The company sold 5.5 million shares at $35.00 per share.
- Estimated net proceeds were approximately $180.3 million, before any exercise of the underwriters’ option.
- The underwriters received an option to purchase up to 825,000 additional shares within 30 days of the February 2, 2021 underwriting agreement.
- The filing does not provide clear values for revenue, net income or loss, operating cash flow, margins, debt, or cash-burn rate.
Material changes versus the prior comparable period
The filing does not present a comparative income statement or cash-flow analysis. The principal disclosed change was the February 2021 equity financing, which increased available capital but increased the company’s outstanding common equity. Shares were delivered on February 5, 2021.
Use of proceeds, outlook and risks
- Proceeds, together with existing liquidity, are intended to fund development of ARQ-151, ARQ-154, ARQ-252 and ARQ-255.
- Planned uses include filing the NDA for ARQ-151 in psoriasis, seeking approval and pursuing commercial launch of ARQ-151 in psoriasis, hiring personnel, working capital and other general corporate purposes.
- Management had not finalized the 2020 financial statements when the preliminary liquidity estimate was disclosed. Adjustments could be identified before completion of the audited consolidated financial statements.
- The preliminary estimate had not been audited, reviewed, compiled or subjected to agreed-upon procedures by Ernst & Young LLP; investors were cautioned not to place undue reliance on it.
- The filing does not provide specific commercialization timing, regulatory approval probability, operating-expense guidance or cash-runway guidance.
Important facts for investors to verify
- Final audited December 31, 2020 cash, cash equivalents, restricted cash and marketable securities.
- Final 2020 revenue, operating expenses, net loss, cash used in operations and cash-burn rate.
- Whether the underwriters exercised all or part of the 825,000-share option and the resulting total proceeds and share count.
- Current clinical, regulatory and commercial status of ARQ-151 and the other development programs.
- Future capital requirements, potential dilution and the company’s expected cash runway following the offering.